标签归档：kp

KP372-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KP372-1  纯度: 99.52%

KP372-1是一种Akt的抑制剂，通过阻断PI3K通路信号，抑制细胞增殖，同时诱导癌细胞凋亡。

KP372-1

KP372-1 Chemical Structure

CAS No. : 1374996-60-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3080 In-stock
5 mg ￥2800 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

KP372-1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

KP372-1, an Akt inhibitor, block signalling through the PI3K pathway and inhibit cell proliferation while inducing apoptosis of cancer cells.

IC50 & Target

PI3-K

 

Akt

 

分子量

448.36

Formula

C20H8N12O2
CAS 号

1374996-60-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 17.86 mg/mL (39.83 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2304 mL 11.1518 mL 22.3035 mL
5 mM 0.4461 mL 2.2304 mL 4.4607 mL
10 mM 0.2230 mL 1.1152 mL 2.2304 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Zaihui Zhang, et al. Heteropolycyclic inhibitors of protein kinases. US7196083B2.

    [2]. Mandal M, Younes M, Swan EA, et al. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol. 2006;42(4):430-439.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KP8顶式三节万向抽气罩

发表于由

【简单介绍】

材质 其他 适用领域 石油,化工,采矿,医药,制药,除尘

KP8顶式三节万向抽气罩 上海金畔生物科技有限公司，您实验室排污浊废气的上佳之选。本产品设计新颖，选材优良，360旋转装置，304不锈钢的关节连接杆以及不易老化之高密度橡胶的关节及密封圈。

【详细说明】

KP8顶式三节万向抽气罩

产品结构介绍：

KP8万向抽气罩: Φ75
关节：高密度PP材质，可360旋转调节方向，易拆卸、重组及清洗。
关节及密封圈：不易老化之高密度橡胶
关节连接杆：304不锈钢
关节松紧旋钮：全铜材质，内嵌不锈钢轴承，于关节连接杆锁合
气流调节阀：手动调节外部阀门旋钮，控制进入之气流量
拱形/杯形集气罩：高密度PP/PC材质
伸缩导管：75mm/PP
特有360旋转装置：以固定架为中心Z大活动半径可达1600mm
固定底座： 模具注塑一体成型，牢度强，不脱底。

产品说明：

   PC需为塑料类中不助燃之材质，且为塑料类中耐高温之材质，符合实
验室安全之需求。

KP8顶式三节万向抽气罩

A B C D E
KP8 990 550 720 520 250
KP8-1 860 350 550 450 250

相关的产品还有：

产品名称

型号

单位

万向抽气罩

KP8（75mm  3.15米）

万向抽气罩

KP8-1（75mm  2.6米）

台
万向抽气罩 KP9
万向抽气罩 KP10

万向抽气罩

KP11（110mm  3.15米）

台

万向抽气罩

KP11-1（110mm  2.6米）

台

新型万向抽气罩

KP12

台
原子抽气罩 KP13

 

KP1019(Synonyms: FFC14A)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KP1019 (Synonyms: FFC14A)

KP1019 (FFC14A) 是一种基于 Ru(III) 的抗转移和细胞毒性抗癌剂。 KP1019 在癌细胞中诱导 DNA 损伤和细胞凋亡 (apoptosis)。

KP1019(Synonyms: FFC14A)

KP1019 Chemical Structure

CAS No. : 124875-20-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells[1][2].

体外研究
(In Vitro)

KP1019 is internalized by yeast and induces mutations, cell cycle delay, and cell death. KP1019 sensitivity of strains defective in DNA repair is examined, ultimately showing that rad1Δ, rev3Δ, and rad52Δ yeast are hypersensitive to KP1019, suggesting that nucleotide excision repair (NER), translesion synthesis (TLS), and recombination each play a role in drug tolerance[1].
KP1019 inhibits proliferation of ovarian tumor cells, induces DNA damage and apoptosis in colon carcinoma cells. KP1019 causes interstrand cross-links and bulky DNA adducts in mammalian cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

KP1019 treatment inhibits primary tumour growth in in the model of MCa mammary carcinoma. None of the treatments reduced the development of lung metastatases in this tumour model[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CBA female mice bearing murine mammary carcinoma[3]
Dosage: 40 mg/kg and 80 mg/kg
Administration: I.P.; two dose levels of 40 mg/kg from day 6 to day 11, and 80 mg/kg on days 7, 9, and 11
Result: Inhibited primary tumour growth.

分子量

598.30

Formula

C21H19Cl4N6Ru
CAS 号

124875-20-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shannon K Stevens, et al. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan;83(1):225-34.

    [2]. Gemma K Gransbury, et al. Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics. 2016 Aug 1;8(8):762-73.

    [3]. A Bergamo, et al. Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs. 2009;2009:681270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KP1019(Synonyms: FFC14A)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KP1019 (Synonyms: FFC14A)

KP1019 (FFC14A) 是一种基于 Ru(III) 的抗转移和细胞毒性抗癌剂。 KP1019 在癌细胞中诱导 DNA 损伤和细胞凋亡 (apoptosis)。

KP1019(Synonyms: FFC14A)

KP1019 Chemical Structure

CAS No. : 124875-20-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells[1][2].

体外研究
(In Vitro)

KP1019 is internalized by yeast and induces mutations, cell cycle delay, and cell death. KP1019 sensitivity of strains defective in DNA repair is examined, ultimately showing that rad1Δ, rev3Δ, and rad52Δ yeast are hypersensitive to KP1019, suggesting that nucleotide excision repair (NER), translesion synthesis (TLS), and recombination each play a role in drug tolerance[1].
KP1019 inhibits proliferation of ovarian tumor cells, induces DNA damage and apoptosis in colon carcinoma cells. KP1019 causes interstrand cross-links and bulky DNA adducts in mammalian cell lines[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

KP1019 treatment inhibits primary tumour growth in in the model of MCa mammary carcinoma. None of the treatments reduced the development of lung metastatases in this tumour model[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CBA female mice bearing murine mammary carcinoma[3]
Dosage: 40 mg/kg and 80 mg/kg
Administration: I.P.; two dose levels of 40 mg/kg from day 6 to day 11, and 80 mg/kg on days 7, 9, and 11
Result: Inhibited primary tumour growth.

分子量

598.30

Formula

C21H19Cl4N6Ru
CAS 号

124875-20-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shannon K Stevens, et al. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan;83(1):225-34.

    [2]. Gemma K Gransbury, et al. Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics. 2016 Aug 1;8(8):762-73.

    [3]. A Bergamo, et al. Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs. 2009;2009:681270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KP1019(Synonyms: FFC14A)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KP1019 (Synonyms: FFC14A)

KP1019 (FFC14A) 是一种基于 Ru(III) 的抗转移和细胞毒性抗癌剂。 KP1019 在癌细胞中诱导 DNA 损伤和细胞凋亡 (apoptosis)。

KP1019(Synonyms: FFC14A)

KP1019 Chemical Structure

CAS No. : 124875-20-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells[1][2].

体外研究
(In Vitro)

KP1019 is internalized by yeast and induces mutations, cell cycle delay, and cell death. KP1019 sensitivity of strains defective in DNA repair is examined, ultimately showing that rad1Δ, rev3Δ, and rad52Δ yeast are hypersensitive to KP1019, suggesting that nucleotide excision repair (NER), translesion synthesis (TLS), and recombination each play a role in drug tolerance[1].
KP1019 inhibits proliferation of ovarian tumor cells, induces DNA damage and apoptosis in colon carcinoma cells. KP1019 causes interstrand cross-links and bulky DNA adducts in mammalian cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

KP1019 treatment inhibits primary tumour growth in in the model of MCa mammary carcinoma. None of the treatments reduced the development of lung metastatases in this tumour model[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CBA female mice bearing murine mammary carcinoma[3]
Dosage: 40 mg/kg and 80 mg/kg
Administration: I.P.; two dose levels of 40 mg/kg from day 6 to day 11, and 80 mg/kg on days 7, 9, and 11
Result: Inhibited primary tumour growth.

分子量

598.30

Formula

C21H19Cl4N6Ru
CAS 号

124875-20-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shannon K Stevens, et al. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan;83(1):225-34.

    [2]. Gemma K Gransbury, et al. Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics. 2016 Aug 1;8(8):762-73.

    [3]. A Bergamo, et al. Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs. 2009;2009:681270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务